In response to the emergence of SARS-CoV-2, she built on her immunology experience to measure humoral (ELISA and multiplex MagPix Bead-based assays) and cellular immune response to SARS-CoV-2 infection and vaccination. She also built capacity to isolate monoclonal antibodies (mAbs) for vaccine and diagnostic development (a GIISER collaboration funded by BMGF). Her focus now is on how to turn R&D program data into impactful public health measures and strategies. Since June 2023, Vigan-Womas has been Coordinator of the CEPI centralized Laboratory at Institut Pasteur de Dakar, focusing on serosurveillance of endemic and epidemic prone diseases (malaria, dengue, chikungunya, Zika, SARS-CoV-2, vaccine preventable diseases andhemorrhagic fever diseases.) She is also a passionate advocate for increasing scientific capacity in Africa and supporting young African scientists
